Autonomix Medical to Present Long-Term Pain Mitigation Data for Pancreatic Cancer at SSO 2026
Event summary
- Autonomix Medical will present long-term clinical data on pain mitigation in pancreatic cancer at the SSO 2026 Annual Meeting.
- The presentation, titled 'Pain Mitigation in Pancreatic Adenocarcinoma: A Long-Term Analysis of Denervation via Transvascular RF Energy-Based Ablation,' is scheduled for March 5-7, 2026, in Phoenix, Arizona.
- Clarke Wilkirson, PhD, will deliver a five-minute presentation followed by a two-minute Q&A session.
- Autonomix's technology focuses on a minimally invasive transvascular RF energy-based approach to address chronic pain in pancreatic cancer patients.
The big picture
Autonomix Medical's presentation at the SSO 2026 Annual Meeting highlights the growing focus on precision nerve-targeted treatments for chronic pain in oncology. The company's transvascular RF energy-based approach represents a potential shift in how debilitating pain associated with pancreatic cancer is managed. This data could position Autonomix as a key player in the medical device sector, particularly in the realm of chronic pain management and surgical oncology.
What we're watching
- Clinical Efficacy
- How the long-term data will impact the perception of Autonomix's technology in addressing chronic pain in pancreatic cancer patients.
- Market Expansion
- Whether Autonomix can leverage this data to expand into other indications beyond pancreatic cancer.
- Regulatory Pathway
- The pace at which Autonomix can progress towards regulatory approval for its investigational technology.
Related topics